Empagliflozin for treating chronic kidney disease

Empagliflozin is in clinical development for the treatment of adult patients with chronic kidney disease (CKD). In CKD, the kidneys do not function as well as they should. This leads to the leakage of blood and protein into the urine. CKD can be developed due to age, but the main risk factors are diabetes, hypertension, acute kidney disease and cardiovascular disease. Some of the symptoms expressed in patients with CKD are headaches, blood in the urine, weight loss and loss of appetite. CKD can occur in both diabetes and non-diabetes mellitus patients. CKD affects around 3 million individuals in the UK therefore additional treatment options are needed.